MedTrace Logo

Fertility Preservation in Men Affected by Cancer

NCT03876366 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2020-03-25

No results posted yet for this study

Summary

This is a single center cross-sectional retrospective study with a quantitative and qualitative approach (phase 1 and 2). In phase 1 an online survey will be realized and targets male cancer survivors. Phase 2 will take a qualitative approach, in which information about patient's experiences, needs and helpful support will be collected by establishing focus groups of cancer patients who had been diagnosed during the reproductive age.

In the end, the results of this study will be integrated into the development of an online support tool concerning Fertility Preservation (FP).

Conditions

Interventions

OTHER

online survey

Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.

OTHER

focus group meeting

Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.

Sponsors & Collaborators

  • Krebsforschung Schweiz, Bern, Switzerland

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Sibil Tschudin, PD Dr. med · Frauenklinik Universitätsspital Basel

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-02
Primary Completion
2020-02-13
Completion
2020-02-13

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03876366 on ClinicalTrials.gov